Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare ...
A director at Complete Solaria Inc bought 606,000 shares at 1.680USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne progr...
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units (“RSUs”) to six newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment ...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medi...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m. ETGoldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025 at 2:40 p.m. ET The fireside chats will be webcast...
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping – Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities an...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Norfolk Southern Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 22 May 2025 in which we reassessed the appropriateness of the ratings in the c...
The Tile Shop to Debut Exclusive Tile Collection With Nate Berkus The Tile Shop x Nate Berkus will arrive at all U.S. Tile Shop showrooms and tileshop.com starting fall 2026. MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- The Tile Shop () today announced a new collaboration with award-winning designer Nate Berkus. The Tile Shop x Nate Berkus, available exclusively at The Tile Shop, will debut in Tile Shop showrooms and on tileshop.com in early fall 2026. The Tile Shop x Nate Berkus collection will feature floor and wall tiles, in a diverse range of materials and shapes, anchored in a pa...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: BoA Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 3:40 p.m. PTTD Cowen’s 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025 at 3:30 p.m. ET The fireside chats will be webcast live and ...
Entrada Therapeutics Reports First Quarter 2025 Financial Results – Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) tod...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.